ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Endometrial Cancer
Breast Cancer
Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Taipei City, TWN:

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (DO-01)

in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...

Enrolling
Ovarian Cancer
Drug: Trastuzumab Deruxtecan
Drug: Bevacizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 179 other locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (TroFuse-021)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as muc...

Enrolling
Ovarian Neoplasms
Ovarian Cancer
Drug: Sacituzumab tirumotecan
Drug: Bevacizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taoyuan District, Taiwan and 12 other locations

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

as "study drug". The study is focused on patients who have advanced ovarian cancer.The aim of the study is to see how safe, tolerab...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Drug: Bevacizumab
Drug: Sarilumab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Taipei, Taiwan and 46 other locations

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian...

Active, not recruiting
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Drug: Paclitaxel
Biological: Placebo

Phase 3

CanariaBio

Taipei, Taiwan and 149 other locations

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer...

Enrolling
Solid Cancer
Drug: PLD
Drug: R-DXd

Phase 2, Phase 3

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 119 other locations

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Nivolumab

Phase 3

pharmaand

Taipei, Taiwan and 237 other locations

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment....

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Drug: H2 receptor antagonist
Biological: Bevacizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 151 other locations

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Peritoneal Neoplasms
Fallopian Tube Cancer
Biological: Bevacizumab
Drug: Placebo for olaparib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 227 other locations

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)

Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at ...

Enrolling
Ovarian Neoplasms
Fallopian Tube Neoplasms
Drug: MIRV
Drug: Sofetabart Mipitecan

Phase 3

Lilly
Lilly

Taipei, Taiwan and 253 other locations

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors (FONTANA)

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer...

Enrolling
Endometrial Cancer
Ovarian Cancer
Drug: Bevacizumab
Drug: Carboplatin

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 59 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems